Tuesday Dec 3
Halozyme Therapeutics' CEO Presents at Piper Jaffray Healthcare Conference
Welcome to the 25th Annual Piper Jaffray Healthcare Conference. Thank you for joining me this afternoon.
Baxter International, Inc. Submits Amended BLA To U.S. FDA for Hyqvia For Primary Immunodeficiency
DEERFIELD, Ill. & SAN DIEGO-- --Baxter International Inc. and Halozyme Therapeutics, Inc. announced today that Baxter has completed submission of an amended biologics license application to the United States Food and Drug Administration to re-initiate the review process for approval of HyQvia [Immune Globulin Infusion 10% with Recombinant Human ... (more)
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
Halozyme Therapeutics, Inc. will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at 12:00 p.m. ET/9:00 a.m. PT .
Halozyme Therapeutics PT Raised to $17.00 at BMO Capital Markets
BMO Capital Markets' price objective indicates a potential upside of 25.65% from the stock's previous close.
Halozyme Therapeutics Price Target Increased to $12.00 by Analysts at Barclays
The firm currently has an "equal weight" rating on the stock. Barclays' target price points to a potential downside of 6.98% from the stock's previous close.